Strategic Focus Target oncology metabolism therapies in early-stage to mid-stage trials, presenting an opportunity to position companion diagnostics, biomarker collaborations, and regulatory affairs support to accelerate development and potential partnerships.

Lead Asset CPI-613 as lead drug with mitochondria-focused metabolism mechanism offers potential collaboration avenues with CROs for trial optimization, manufacturing scale-up discussions, and potential co-development talks with larger pharma partners seeking novel anti-cancer modalities.

Clinical Progress Active Phase I to II studies indicate ongoing clinical activity; engage clinical researchers, KOLs, and contract research organizations to discuss trial expansion, site networks, and data generation strategies that could attract licensing or collaboration deals.

Finance & Growth Funding and revenue profile suggests a strategic window for partnering with mid-cap and larger pharma companies seeking asset diversification; explore upfronts, milestone structures, and co-development financing opportunities.

Strategic Partnerships Past collaborations and leadership changes imply a dynamic ecosystem; identify potential alliance targets in Roswell Park-type research networks and oncology metabolism spaces to accelerate research, manufacturing, and global commercialization planning.